Table 3 Comparison of OS and PRS between the asymptomatic and symptomatic MBC groups according to subtype.

From: Prognosis of asymptomatic versus symptomatic metastatic breast cancer: a multicenter retrospective study

 

Overall survival (months)

95% Confidence interval

p-value

Post-recurrence survival (months)

95% Confidence interval

p-value

Luminal

Asymptomatic MBC

112

98–150

0.91

54

48–73

0.08

Symptomatic MBC

124

72–146

 

41

29–56

 

HER2

Asymptomatic MBC

113

59–195

0.40

71

25–89

0.09

Symptomatic MBC

72

49–112

 

27

16–57

 

Triple negative

Asymptomatic MBC

46

24–112

0.06

28

8–100

0.01

Symptomatic MBC

37.5

19–63

 

10.5

5–23

 
  1. HER2 human epidermal growth factor receptor 2, MBC metastatic breast cancer, OS overall survival, PRS post-recurrence survival.